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A B S T R A C T
Antibody-mediated humoral immunity is thought to play a central role in mediating the immunopathogene-
sis of acute DENV infection, but limited data are available on the diversity, specificity, and functionality of the
antibody response at the molecular level elicited by primary or secondary DENV infection. In order to close
this functional gap in our understanding of DENV-specific humoral immunity, we utilized high-throughput
single cell RNA sequencing to investigate B cells circulating in both primary and secondary natural DENV
infections. We captured full-length paired immunoglobulin receptor sequence data from 9,027 B cells from a
total of 6 subjects, including 2,717 plasmablasts. In addition to IgG and IgM class-switched cells, we unex-
pectedly found a high proportion of the DENV-elicited plasmablasts expressing IgA, principally in individuals
with primary DENV infections. These IgA class-switched cells were extensively hypermutated even in indi-
viduals with a serologically confirmed primary DENV infection. Utilizing a combination of conventional bio-
chemical assays and high-throughput shotgun mutagenesis, we determined that DENV-reactive IgA class-
switched antibodies represent a significant fraction of DENV-reactive Igs generated in response to DENV
infection, and that they exhibit a comparable epitope specificity to DENV-reactive IgG antibodies. These
results provide insight into the molecular-level diversity of DENV-elicited humoral immunity and identify a
heretofore unappreciated IgA plasmablast response to DENV infection.









DENV is a positive-sense single-stranded RNA virus of the family
Flaviviridae, genus Flavivirus, that is maintained in a primarily anthro-
ponotic cycle between the Aedes aegypti mosquito and humans [1].
Consisting of four genetically and immunologically distinct serotypes
(DENV-1, 2, 3, and 4), DENV is thought to infect between 280 and
550 million people worldwide every year, with as many as 100 million
infections resulting in some degree of clinical presentation [2,3]. While
DENV infection is subclinical in the majority of cases, in susceptible
individuals it can cause a debilitating flu-like illness known as dengue
fever. The majority of individuals suffering from dengue fever recover
without the need for extensive medical intervention, but approxi-
mately 500,000 individuals per year develop severe dengue, dengue
hemorrhagic fever/dengue shock syndrome (DHF/DSS), which has a
mortality rate of up to 20% [47].
A unique epidemiological feature of DENV infection is that severe
immunopathological symptoms are more likely to occur in individuals
previously infected with a heterologous viral serotype compared to
individuals without any preexisting DENV immunity [8]. While the
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mechanisms behind the multifaceted immunopathogenesis of dengue
are incompletely understood and may involve some degree of genetic
predisposition [9,10], waning antibody-mediated cross-recognition of
heterotypic DENV is one potential explanation for the increased fre-
quency of severe disease in individuals experiencing a secondary
DENV infection [5,11]. Antibody-dependent enhancement (ADE) of
DENV infection has been observed in various in vitro experimental
models and in in vivo adoptive transfer models [5,1215], and is
thought to be primarily facilitated by Fc-receptor mediated endocyto-
sis of IgG1-opsonized DENV particles [1618]. Even though discrete
DENV E protein antibody epitopes have been identified as particularly
amenable to antibody-mediated immune enhancement of infection
[19], any DENV-reactive IgG1 antibody with a low IC50/EC50 ratio is
theoretically capable of enhancing DENV infection when present at an
appropriate concentration [2022]. However, while significant correl-
ative data exist, definitive in vivo evidence of ADE in humans has been
elusive. Therefore, understanding the molecular diversity of DENV-eli-
cited humoral immunity is critical for extending our understanding of
risk factors associated with severe dengue, especially the relative
abundance of antibody subclasses with the potential for promoting or
inhibiting ADE.
The primary source of circulating DENV-reactive antibodies per-
sisting after the resolution of infection are non-dividing, terminally
differentiated, bone-marrow resident, plasma cells [2325]. How-
ever, while plasma cell-derived antibodies take several weeks to
peak and stabilize after initial antigen exposure, B cell plasmablasts
can be found in circulation just days after an initial pathogen expo-
sure [23,24,26]. The majority of plasmablasts generated in response
to infection rapidly undergo apoptosis following the resolution of
inflammation, but a fraction of these cells terminally differentiate
into long-lived plasma cells and take-up residency in the bone mar-
row [25,2729]. A direct precursor/progeny relationship has been
demonstrated for plasmablasts and plasma cells in animal studies,
and the frequency of plasmablast-phenotype B cells circulating
510 days after vaccination has been shown to positively correlate
with serum antibody titers achieved several weeks after DENV anti-
gen exposure [3034].
The functional relationship between DENV-elicited plasmablasts
and the durable humoral immune profile present after the resolution
of infection is further reinforced by work assessing the clonal diver-
sity and antigen specificity of the plasmablast population generated
in response to DENV infection. Previous work has demonstrated that
the plasmablasts elicited by a secondary DENV infection primarily
express broadly cross-reactive, moderately neutralizing, and exten-
sively hypermutated immunoglobulins [32,3537]. This antigen
specificity is reminiscent of the humoral immune profile observed in
most individuals following resolution of a secondary DENV infection
[33]. In all of these studies, 70%90% of the immunoglobulins
expressed by circulating plasmablasts were observed to bind DENV,
and the overwhelming majority of the plasmablasts appear to be
derived from memory B cells, as indicated by both the relatively
restricted clonal diversity of the population, as well as the extensive
pre-existing SHM burden of the antibodies [32,3537].
In contrast to the abundance of data available on the plasmablast
phenotype associated with secondary DENV infection, relatively little
data are available on the immunoglobulin receptor specificity and
functionality of plasmablasts circulating in response to a primary
DENV infection. The most well characterized dataset addressing this
question is derived from a human primary dengue serotype 2 infec-
tion model [38]. As in secondary DENV infection, abundant plasma-
blast expansion was observed following infection. However, in
contrast to the specificity and functional profile of immunoglobulins
generated in response to secondary DENV infection, only ~40% of
plasmablast-derived antibodies reacted with DENV, with the major-
ity of antibodies exhibiting serotype-specific reactivity and generally
poor neutralization potential. Again, this profile closely mirrors the
functional profile of serum following primary DENV infection [39,40].
Although these previous studies provide valuable insight into the
molecular complexity of the humoral immune response elicited by
DENV infection, there are several significant limitations inherent
within the current publication record. Firstly, no data are available on
the plasmablast-derived immunoglobulin diversity and functionality
following natural primary DENV infection. Secondly, the aforemen-
tioned studies restricted their immunoglobulin receptor analysis to
cells that expressed IgG or IgM, either by up-front selection during the
cell isolation procedure or by virtue of the primers used to amplify the
immunoglobulin receptor sequences [32,3537]. This lack of an unbi-
ased approach to the analysis of plasmablast and immunoglobulin
receptor sequence diversity leaves open the possibility that significant
features of the humoral immune profile associated with either primary
or secondary infection may have been overlooked. Filling this potential
knowledge gap may generate new tools for the rapid clinical assess-
ment of previous DENV exposure, and may also provide some insight
into the divergent clinical outcomes observed following either primary
or secondary DENV infection.
To fill this knowledge gap, we utilized single cell RNA sequencing
technology to assess the clonal and transcriptional diversity of plasma-
blasts elicited in response to primary and secondary DENV infections
in an unbiased and high-throughput fashion. Using this approach, we
were able to capture full-length paired immunoglobulin receptor
sequence data from 9,027 B cells circulating in response to both pri-
mary and secondary DENV infection, including 2,717 DENV-elicited
plasmablasts. We found an unexpectedly high proportion of plasma-
blasts expressing IgA in PBMC from patients with primary infection, in
addition to the expected IgG and IgM class-switched plasmablasts.
These IgA class-switched cells were extensively hypermutated, even in
individuals with serologically confirmed primary DENV infection. IgA
class-switched Igs expressed by plasmablasts in both primary and
Research in context
Evidence before this study
Antibody-mediated humoral immunity is thought to play a cen-
tral role in mediating the immunopathogenesis of acute DENV
infection. However, limited data are available on the molecu-
lar-level diversity, specificity, and functionality of the antibody
response elicited by primary or secondary DENV infection. At
the onset of this study in 2018 we queried Pubmed for articles
either directly comparing/contrasting the plasmablast immu-
noglobulin repertoires elicited by either primary or secondary
DENV infection, or for articles that assessed the DENV-elicited
plasmablast repertoires in an unbiased fashion without up-
front immunoglobulin isotype selection. No previously pub-
lished report satisfied either of these criteria.
Added value of this study
Our study is the first to examine the molecular level diversity and
antigen specificity of the plasmablast antibody repertoire elicited
by both primary and secondary dengue in an unbiased and high-
throughput fashion. This approached revealed a previously unap-
preciated role for DENV-reactive IgA in both primary and secondary
dengue, with IgA the dominant plasmablast-restricted isotype
observed following primary DENV infection.
Implications of all the available evidence
These results identify a heretofore unappreciated role for
DENV-reactive IgA in the humoral response to DENV infection,
especially in the setting of primary DENV infection.
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secondary DENV infections neutralized DENV and reacted with canoni-
cal epitopes on the DENV E protein. Our data demonstrate a previously
unappreciated role for IgA class-switched B cells during acute DENV
infection - especially during a primary DENV infection - and highlight
the utility of unbiased scRNAseq analysis in identifying novel immuno-
logical consequences of viral infection.
2. Materials and methods
2.1. Sample collection
Peripheral blood mononuclear cells (PBMC) and plasma were iso-
lated from whole blood specimens obtained from children enrolled in
a hospital-based acute illness study in Bangkok, Thailand, the design of
which has been previously described [41,42]. Blood samples were
obtained serially during acute infection and at early and late conva-
lescent time points; the term ‘fever day’ is used to report acute illness
time points relative to Day 0, defined as the day of defervescence. The
infecting virus type (DENV-1-4) was determined by RT-PCR and/or
virus isolation as previously described [43], and serology (EIA and HAI
assays) was used to distinguish primary and secondary DENV infec-
tions [44]. Written informed consent was obtained from each subject
and/or his/her parent or guardian. The study protocol was approved
by the Institutional Review Boards of the Thai Ministry of Public
Health, the Office of the U.S. Army Surgeon General, the University of
Massachusetts Medical School, and the University of Rhode Island.
PBMC and plasma samples were cryopreserved for later analysis.
2.2. Flow cytometry and cell sorting
Cryopreserved PBMC were thawed and placed in RPMI 1640
medium supplemented with 10% heat-inactivated normal human
serum (100318, Gemini Bio-Products), L-glutamine, penicillin, and
streptomycin prior to analysis. Cell viability was assessed using CTL-
LDC Dye (Cellular Tecnology Limited [CTL], Shaker Heights, OH) and a
CTL-ImmunoSpot S6 Ultimate-V Analyzer (CTL). Surface staining for
flow cytometry analysis and cell sorting was performed in PBS sup-
plemented with 2% FBS at room temperature. Aqua Live/Dead (Ther-
moFisher, L34957) was used to exclude dead cells in all experiments.
Antibodies and dilutions used for flow cytometry analysis are listed
in Supplemental Table 7. Cell sorting was performed on a BD FACSA-
ria Fusion instrument, and data analyzed using FlowJo v10.2 software
(Treestar).
2.3. Single-cell RNA sequencing library generation
Flow-sorted viable B and T cell suspensions were prepared for sin-
gle-cell RNA sequencing using the Chromium Single-Cell 50 Reagent
version 2 kit and Chromium Single-Cell Controller (10x Genomics, CA)
[45]. Approximately 20008000 cells per reaction suspended at a den-
sity of 50500 cells/mL in PBS plus 0.5% FBS were loaded for gel bead-
in-emulsion (GEM) generation and barcoding. Reverse transcription,
RT-cleanup, and cDNA amplification were performed to isolate and
amplify cDNA for downstream 50 gene or enriched V(D)J library con-
struction according to the manufacturer’s protocol. Libraries were con-
structed using the Chromium Single-Cell 50 reagent kit, V(D)J Human B
Cell Enrichment Kit, 30/50 Library Construction Kit, and i7 Multiplex Kit
(10x Genomics, CA) according to the manufacturer’s protocol.
2.4. Sequencing
scRNAseq 50 gene expression libraries and BCR V(D)J enriched
libraries were sequenced on an Illumina NovaSeq 6000 instrument
using the S1, S2, or S4 reagent kits (300 cycles). Libraries were bal-
anced to allow for ~150,000 reads/cell for 50 gene expression libraries,
and ~20,000 reads/cell for BCR V(D)J enriched libraries. Sequencing
parameters were set for 150 cycles for Read1, 8 cycles for Index1, and
150 cycles for Read2. Prior to sequencing, library quality and concen-
tration were assessed using an Agilent 4200 TapeStation with High
Sensitivity D5000 ScreenTape Assay and Qubit Fluorometer (Thermo
Fisher Scientific) with dsDNA BR assay kit according to the manufac-
turer’s recommendations.
2.5. 50 gene expression analysis/visualization
The 50 gene expression alignment from sorted PBMC was per-
formed using the 10x Genomics Cell Ranger pipeline [45]. Sample
demultiplexing, alignment, barcode/UMI filtering, and duplicate com-
pression was performed using the Cell Ranger software package (10x
Genomics, CA, v2.1.0) and bcl2fastq2 (Illumina, CA, v2.20) according to
the manufacturer’s recommendations, using the default settings and
mkfastq/count commands, respectively. Transcript alignment was per-
formed against a human reference library generated using the Cell
Ranger mkref command and the Ensembl GRCh38 v87 top-level
genome FASTA and the corresponding Ensembl v87 gene GTF.
Multi-sample integration, data normalization, visualization, and
differential gene expression was performed using the R package
Seurat (v3.0) [46,47]. Non-viable cells and doublets were filtered
from the dataset by removing cells with >10% mitochondrial RNA
content, and those cells expressing fewer than 200 or more than
6,000 unique genes. Differential gene expression analysis was per-
formed using a Wilcoxon rank sum test with Bonferoni correction to
control for False Discovery Rate (FDR).
2.6. Immunoglobulin sequence analysis
Sorted B cell immunoglobulin clonotype identification, alignment,
and annotation was performed using the 10x Genomics Cell Ranger
pipeline. Sample demultiplexing and clonotype alignment was per-
formed using the Cell Ranger software package (10x Genomics, CA,
v2.1.0) and bcl2fastq2 (Illumina, CA, v2.20) according to the manufac-
turer’s recommendations, using the default settings and mkfastq/vdj
commands, respectively. Immunoglobulin clonotype alignment was
performed against a filtered human V(D)J reference library generated
using the Cell Ranger mkvdjref command and the Ensembl GRCh38
v87 top-level genome FASTA and the corresponding Ensembl v87
gene GTF. Immunoglobulin clonotype visualization, diversity assess-
ment, and analysis were performed using either the Loupe VDJ
Browser (10x Genomics, CA, v2.0.0) or custom R code. Paired immu-
noglobulin clonotype identity, hypermutation burden, and clonal
lineage was assessed using the software package BRILIA, with a 15%
sequence similarity threshold for clonal lineage assignment [48].
Heavy chain restricted framework and CDR hypermutation burdens
were calculated using the IMGT/HighV-QUEST server [49].
2.7. Recombinant monoclonal antibody synthesis
The variable regions from the heavy and light chains of targeted
immunoglobulin sequences were codon optimized, synthesized in
vitro and subcloned into a pcDNA3.4 vector containing the human
IgG1 Fc region by a commercial partner (Genscript). Transfection
grade plasmids were purified by maxiprep and transfected into a
293-6E expression system. Cells were grown in serum-free FreeStyle
293 Expression Medium (Thermo Fisher), and the cell supernatants
collected on day 6 for antibody purification. Following centrifugation
and filtration, the cell culture supernatant was loaded onto an affinity
purification column, washed, eluted, and buffer exchanged to the
final formulation buffer (PBS). Antibody lot purity was assessed by
SDS-PAGE, and the final concentration determined by 280 nm
absorption. The clonotype information for all monoclonal antibodies
generated as part of this study is listed in Supplemental Table 2.
A.T. Waickman et al. / EBioMedicine 54 (2020) 102733 3
2.8. Viruses
DENV-1-4 (strains Nauru/West Pac/1974, S16803, CH53489, and
TVP-360, respectively) propagated in C6/36 mosquito cells were uti-
lized for ELISA, FlowNT50, and ADE assays. Virus for ELISA was puri-
fied by ultracentrifugation through a 30% sucrose solution and the
virus pellet was resuspended in PBS.
2.9. Monoclonal antibody DENV-capture ELISA
Monoclonal antibody DENV reactivity was assessed using a 4G2
DENV capture ELISA protocol. In short, 96 well NUNC MaxSorb flat-
bottom plates were coated with 2 mg/ml flavivirus group-reactive
mouse monoclonal antibody 4G2 (Envigo Bioproducts, Inc.) diluted in
borate saline buffer. Plates were washed and blocked with 0.25%
BSA + 1% Normal Goat Serum in PBS after overnight incubation.
DENV-1, -2, -3 or -4 (strains Nauru/West Pac/1974, S16803,
CH53489, and TVP-360) were captured for 2 h in the appropriate
wells, followed by extensive washing. Serially diluted monoclonal
antibody samples were incubated for 1 h at RT on the captured virus,
and DENV-specific antibody binding quantified using anti-human IgG
HRP (Sigma-Aldrich, SAB3701362). Secondary antibody binding was
quantified using the TMB Microwell Peroxidase Substrate System
(KPL, cat. #50-76-00) and Synergy HT plate reader (BioTek, Winooski,
VT). Antibody data were analyzed by nonlinear regression (One site
total binding) to determine EC50 titers in GraphPad Prism 8 (Graph-
Pad Software, La Jolla, CA).
2.10. Flow cytometry-based 50% neutralization (FlowNT50) assay
Neutralizing antibody titers of monoclonal antibodies and heat-
inactivated sera were determined using a flow cytometry-based neu-
tralization assay in U937 cells expressing DC-SIGN as previously
described [50,51]. Serial dilutions of antibody or sera were mixed
with an equal volume of virus, diluted to achieve 10%15% infection
of cells/well, and incubated for 1 h at 37 °C. After 1 h of incubation,
an equal volume of medium (RPMI-1640 supplemented with 10%
FBS, 1% penicillin/streptomycin, 1% L-glutamine (200 mM), and 1%
nonessential amino acids (10 mM)) containing 5 £ 104 U937-DC-
SIGN cells were added to each serum-virus mixture and incubated
1820 h overnight in a 37 °C, 5% CO2, humidified incubator. Follow-
ing overnight incubation, the cells were fixed, permeabilized and
immunostained with flavivirus group-reactive mouse monoclonal
antibody 4G2 (Envigo Bioproducts, Inc.), and secondary polyclonal
goat anti-mouse IgG PE-conjugated antibody (#550589, BD Bioscien-
ces). The percentage of infected cells were quantified on a BD Accuri
C6 Plus flow cytometer (BD Biosciences). Data were analyzed by non-
linear regression to determine 50% neutralization titers in GraphPad
Prism 8 (GraphPad Software, La Jolla, CA).
2.11. Antibody-dependent enhancement (ADE) assay
In vitro antibody-dependent enhancement of DENV infection was
quantified as previously described [52]. Two-fold serial dilutions of
antibody or heat-inactivated sera were incubated with virus (in suffi-
cient amounts to infect 10%15% of U937-DC-SIGN cells) at 1:1 for
1 h at 37 °C. This mixture was then added to a 96-well plate contain-
ing 5 £ 104 cells (K562) per well in duplicate. Cells were infected
1820 h overnight in a 37 °C, 5% CO2, humidified incubator. Process-
ing and quantification continued as outlined in the FlowNT50 meth-
ods. Fold-infection relative to control serum was reported.
2.12. Serum IgG/IgM/IgA ELISA
DENV-reactive serum IgM/IgG/IgA levels were assessed using a
modified 4G2 DENV capture ELISA protocol. 96 well NUNC MaxSorb
flat-bottom plates were coated with 2 mg/ml flavivirus group-
reactive mouse monoclonal antibody 4G2 (Envigo Bioproducts, Inc.)
diluted in borate saline buffer. Plates were washed and blocked with
0.25% BSA +1% Normal Goat Serum in PBS after overnight incubation.
DENV-1 (strain Nauru/West Pac/1974) was captured for 2 h in sepa-
rate wells, followed by extensive washing. Serially diluted serum
samples were plated in duplicate and incubated for 1 h at RT on the
captured virus. DENV-specific IgM/IgG/IgA levels were quantified
using anti-human IgM HRP (Seracare, 5220-0328), anti-human IgG
HRP (Sigma-Aldrich, SAB3701362), and anti-human IgA HRP (Biole-
gend, 411,002). Secondary antibody binding was quantified using the
TMB Microwell Peroxidase Substrate System (KPL, cat. #50-76-00)
and Synergy HT plate reader. Single-dilution ELISA was performed
using a 1/500 serum dilution for IgM and IgA assays, and a 1/20,000
serum dilution for IgG assays.
2.13. Shotgun mutagenesis epitope mapping
Epitope mapping was performed as outlined previously [53].
Expression constructs for prM/E from DENV-1 (strain Nauru/West Pac/
1974) and DENV-2 (strain 16681) were subjected to high-throughput
‘Shotgun Mutagenesis’ to generate comprehensive mutation libraries,
with each prM/E polyprotein residue mutated to alanine (and alanine
residues to serine), which were arrayed into 384-well plates (one muta-
tion per well). For MAb library screening, plasmids encoding the DENV
protein variants were transfected individually into human HEK-293T
cells and allowed to express for 22 h before fixing cells in 4% parafor-
maldehyde (Electron Microscopy Sciences), and permeabilizing with
0.1% (w/v) saponin (Sigma-Aldrich) in PBS plus calcium andmagnesium
(PBS++). Cells were incubated with purified mAbs (0.12.0 mg/mL)
diluted in 10% NGS (Sigma)/0.1% saponin, pH 9.0. Before screening, the
optimal concentration was determined for each antibody, using an
independent immunofluorescence titration curve against wild-type
prM/E to ensure that signals were within the linear range of detection
and that signal exceeded background by at least 5-fold. Antibodies
were detected using 3.75 mg/mL Alexa Fluor 488-conjugated secondary
antibody (Jackson ImmunoResearch Laboratories) in 10% NGS/0.1%
saponin. Cells were washed three times with PBS++/0.1% saponin fol-
lowed by 2 washes in PBS. Mean cellular fluorescence was detected
using an Intellicyt high throughput flow cytometer (HTFC, Intellicyt).
Antibody reactivity against each mutant protein clone was calculated
relative to reactivity with wild-type prM/E, by subtracting the signal
from mock-transfected controls and normalizing to the signal from
wild-type protein-transfected controls. The entire library data for each
mAb were compared to the equivalent data from control mAbs. Muta-
tions within clones were identified as critical to the MAb epitope if they
did not support reactivity of the test MAb, but supported reactivity of
other, control antibodies. This counter-screen strategy facilitates the
exclusion of DENV prM/E protein mutants that are mis-folded or have
an expression defect.
2.14. Statistical analysis
All statistical analysis was performed using GraphPad Prism 8
Software (GraphPad Software, La Jolla, CA). A P-value<0.05 was con-
sidered significant.
3. Results
3.1. Robust B cell plasmablast circulation occurs following primary and
secondary DENV infection
Following introduction into a human host by an infected mosquito
during blood meal acquisition, DENV asymptomatically replicates for
314 days prior to the onset of measurable viremia or any clinical
manifestation of infection (Fig. 1a) [54]. As the precise interval
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between when an individual is infected with DENV and when vire-
mia/symptoms manifest is highly variable, the day of defervescence
(referred here as “fever day 0”) is used as a reference point to stan-
dardize the kinetics of infection-associated immunopathology. While
viremia generally resolves by fever day 0, lymphocyte activation in
the periphery is generally not detectable until just before fever abate-
ment, with maximal T and B cell activation occurring in the subse-
quent 35 days (“early convalescence”; Fig. 1a) [34,5557]. While
this kinetic profile has been described in previous studies of second-
ary DENV infection, limited data are available regarding the func-
tional diversity of plasmablasts activated in response to both primary
and secondary DENV infection. Therefore, to determine if there are
any differences in the phenotype and immunoglobulin repertoire of
plasmablasts activated in response to either primary or secondary
DENV infection, we analyzed PBMC from 6 pediatric patients with
serologically confirmed primary or secondary DENV infection.
We first analyzed the frequency of circulating plasmablasts
during the acute (febrile) and early convalescent period by flow
cytometry. Consistent with other previously published reports
[34,5557], robust plasmablast expansion was observed in PBMC
of subjects with primary and secondary DENV infections. For indi-
viduals with serologically confirmed primary DENV infections, a
significant population of plasmablasts were observed at two time-
points per subject (1 acute, early convalescent) (Fig. 1b and Sup-
plemental Fig. 1), and individuals with serologically confirmed
secondary DENV infections exhibited significant plasmablast
expansion over three time points (2 acute, 1 early convalescent)
(Fig. 1c and Supplemental Fig. 1).
3.2. Identification and transcriptional characterization of DENV-elicited
B cell plasmablasts by scRNAseq following primary or secondary DENV
infection
To better understand the clonal and transcriptional diversity of
the plasmablast repertoire elicited by primary and secondary DENV
infections, we subjected sorted total CD3+ T cells and CD19+ B cells
from the samples highlighted in Fig. 1 to single cell RNA sequencing
(scRNAseq) analysis using the 10x Genomics platform (Supplemental
Fig. 2). Cells were processed so as to recover both the unbiased 50
gene expression profile from each cell, as well as the paired full-
length immunoglobulin sequences utilizing targeted nested PCR. B
cells were identified within the parental dataset and extracted for
subsequent targeted analysis. Using this approach, we recovered a
total of 9,027 B cells with high-quality transcriptomic and immunore-
ceptor data from the 6 subjects included in our analysis (range,
2601281 per subject-time point). Four transcriptionally distinct
populations of B cells were identified within the total captured B cell
pool by unsupervised hierarchical clustering of the cells based on
their complete gene expression profile (Fig. 2a). Differential gene
expression analysis of these four statistically distinct B cell popula-
tions determined that these clusters correspond to canonical naïve B
cells, memory B cells, plasmablasts, and pre-plasmablasts (Fig. 2b and
c, Supplemental Table 1). Consistent with their ascribed functional
potential, transcriptional imputation of the cell-cycle stage of the B
cells captured in this dataset revealed that the naïve B cells, memory
B cells, and plasmablasts were primarily in the G1 stage of the cell
cycle, while pre-plasmablasts were exclusively in G2M/S (Fig. 2d). All
Fig. 1. Kinetics of B cell plasmablast circulation following natural primary and secondary DENV infection. Plasmablast phenotype B cells (CD19+CD27+CD38+) are evident in circula-
tion following both primary and secondary natural DENV infection. (A) Schematic representation of dengue kinetics and PBMC sample collection. (B) Quantification of plasmablast
phenotype B cell frequency in subjects with serologically confirmed primary DENV infections by flow cytometry. (C) Quantification of plasmablast phenotype B cell frequency in
subjects with serologically confirmed secondary DENV infection by flow cytometry.
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Fig. 2. Identification, quantification, and transcriptional characterization of B cell subsets by scRNAseq. Conventional B cell subset identification by unsupervised hieratical clustering of scRNAseq
data from individuals with primary and secondary DENV infections. (A) UMAP projection of transcriptionally defined B cell populations from all subjects/time points included in this analysis
with key populations demarcated. (B) Expression of canonical key B cell lineage genes across all cells in the dataset. (C) Heatmap ofmost differentially expressed gene products as defined byWil-
coxon Log Rank test distinguishing naïve B cells, memory B cells, plasmablasts, and pre-plasmablasts across all subjects and time points. Data are down-sampled to 200 cells/population for visual-
ization. (D) Imputation of cell cycle stage based on the expression of canonical cell-cycle stage associated gene products within naïve B cells, memory B cells, plasmablasts and pre-plasmablasts in
the integrated dataset. (E) Abundance of naïve B cells, memory B cells, plasmablasts, and pre-plasmablasts longitudinally within each subject in the study as defined by scRNAseq. (F) Correlation
analysis of the frequency of B cell plasmablasts as defined by flow cytometry and scRNAseq for all subjects and time points within the study. r2 and p value calculated by linear regression.
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four distinct populations of B cells were identified within each sub-
ject at each timepoint, with significant population expansion/con-
traction observed in each subject (Table 1, Fig. 2e). The frequency of
plasmablasts as assessed by scRNAseq analysis of sorted CD19+ B cells
correlated with the results obtained from flow-cytometry analysis of
the same samples (Fig. 2f).
3.3. Isotype distribution and somatic hypermutation burden of
immunoglobulins expressed by circulating B cells during primary and
secondary natural DENV infection
Using the population identifiers assigned by the transcriptional
profile of the B cells captured in our scRNAseq analysis, we assessed
the antibody isotype diversity and immunoglobulin somatic hypermu-
tation (SHM) burden of naïve B cells, memory B cells, and plasma-
blasts/pre-plasmablasts present in individuals experiencing primary
or secondary DENV infections. As pre-plasmablasts and plasmablasts
are direct clonal relatives and only differ in their stage of the cell cycle,
(Fig. 1c and d, Supplemental Table 1) [24,58], these two populations
were merged in all subsequent immunoglobulin receptor analysis. To
maximize data quality in downstream evaluation, immunoglobulin
sequence analysis was restricted to those cells from which a single
paired full-length heavy chain and full-length light chain sequence
was obtained.
Consistent with their canonical profile, the Ig sequences expressed
by transcriptionally-demarcated naïve B cells were observed to be IgD
or IgM in isotype with little-or-no SHM away from their germline con-
figuration (Fig. 3a and d). No difference in the isotype distribution or
SHM burden was observed within the naïve B cell compartment
between individuals with primary versus secondary DENV infection.
In contrast, transcriptionally-defined memory B cells were observed to
express Igs with a diverse array of isotypes, including IgA1, IgA2, IgG1,
IgG2, IgG3, IgM, and to a lesser extent IgD (Fig. 3b). However, no differ-
ence in the isotype distribution of the Igs expressed by memory B cells
was observed in PBMC from individuals with primary versus second-
ary DENV infection. The SHM burden of the IgM, IgG, and IgA immuno-
globulins expressed by memory B cells were higher than those
observed in naïve B cells, with IgG and IgA class-switched memory B
cells having a significantly higher SHM burden than their IgM express-
ing counterparts (Fig. 3e). No difference in the SHM burden was
observed in the IgM, IgG, and IgA expressing memory B cell compart-
ment between individuals with primary versus secondary DENV infec-
tion.
In contrast to the modest differences in isotype distribution and
SHM burden observed in naïve and memory B cells identified in indi-
viduals with primary versus secondary DENV infections, significant
differences were observed within the corresponding plasmablast
compartments. Plasmablasts identified in individuals with primary
DENV infections had nearly equal ratios of IgA, IgG and IgM express-
ing cells, while individuals experiencing a secondary DENV infection
exhibited a significant IgG1 bias within the plasmablast compart-
ment, with only modest IgA or IgM representation (Fig. 3c and Sup-
plemental Fig. 3, Table 2). No difference was observed in the SHM
burden of the IgM expressing plasmablasts between individuals with
either primary or secondary DENV infections, while IgG expressing
plasmablasts from individuals with a secondary DENV infection
exhibited a significantly higher SHM burden than their counterparts
from individuals with primary DENV infections (Fig. 3f and Supple-
mental Fig. 3). Surprisingly, the IgA class-switched plasmablasts in
both primary and secondary DENV infections exhibited an equally
high SHM burden, with the accumulation of mutations following sim-
ilar patterns in both the framework regions and CDRs of the antibod-
ies (Fig. 3f and Supplemental Figs. 3 and 4). This is despite the fact
that by all other metrics the individuals classified as experiencing a
primary DENV infection have never encountered DENV antigen pre-
viously. Therefore, in addition to the anticipated differences in IgM
and IgG expressing plasmablasts, we contend that primary DENV
infection can be characterized by a high relative proportion of exten-
sively hypermutated IgA expressing plasmablasts. Clonal expansion
was evident in the both the IgG and IgA expressing plasmablast com-
partments from subjects with either primary or secondary DENV
infection (Supplemental Fig. 5), but no discernable trend or enrich-
ment in Ig gene segment usage was evident (Supplemental Fig. 6).
3.4. Functional characterization of DENV-elicited plasmablast
immunoglobulins
To determine the antigen specificity and functional potential of
the Igs expressed by DENV-elicited plasmablasts captured in our
scRNAseq dataset  especially IgA class-switched cells - we synthe-
sized 520 monoclonal antibodies (mAb) from each subject included
in our analysis. We selected Ig sequences based on the clonal abun-
dance of the sequence and the amount of the Ig transcript expressed
within the corresponding plasmablast (> 1000 copies/cell). The only
exception to these criteria were VDB-5, -6,- 7, and -8, which were
selected based on their clonal relationship to VDB-2. Using these
benchmarks, we selected and synthesized a total of 56 mAbs from
DENV-elicited plasmablasts: 21 from individuals with primary DENV
infection and 35 from individuals with secondary DENV infection
(Supplemental Table 2). Within the selected pool of mAb candidates
were antibodies with parental IgM, IgG1, IgG3, and IgA1 isotypes. The
mAbs were screened for the ability to bind DENV-1, -2, -3 and -4 by
Table 1
Subject, timepoint, and cell-type information.
Subject Age / Sex Infection Serotype Severity Time point (fever day) Total B cells Cell type breakdown
Naïve Memory Plasmablast Pre-plasmablast
Primary #1 9/M Primary DENV1 DF 1 430 146 (33.9%) 246 (57.2%) 28 (6.5%) 10 (2.3%)
3 525 168 (32%) 278 (52.9%) 71 (13.5%) 8 (1.5%)
Primary #2 9/M Primary DENV1 DF 1 554 90 (16.2%) 228 (41.1%) 185 (33.4%) 51 (9.2%)
5 521 215 (41.2%) 266 (51.1%) 33 (6.3%) 7 (1.3%)
Primary #3 5/M Primary DENV1 DF 1 693 434 (62.6%) 233 (33.6%) 22 (3.2%) 4 (0.5%)
2 432 112 (25.9%) 166 (38.4%) 112 (25.9%) 42 (9.7%)
Secondary #1 12/M Secondary DENV3 DHF 0 562 49 (8.7%) 78 (13.9%) 355 (63.2%) 80 (14.2%)
1 1002 165 (16.5%) 288 (28.7%) 391 (39%) 158 (15.8%)
7 741 432 (58.3%) 300 (40.5%) 8 (1.1%) 1 (0.01%)
Secondary #2 13/F Secondary DENV1 DHF 1 427 178 (41.7%) 131 (30.7%) 79 (18.5%) 39 (9.1%)
1 1281 285 (22.2%) 299 (23.3%) 576 (45%) 121 (9.4%)
5 865 452 (52.2%) 376 (43.5%) 31 (3.6%) 6 (0.7%)
Secondary #3 11/F Secondary DENV1 DF 0 260 103 (39.6%) 96 (36.9%) 53 (20.4%) 8 (3.1%)
1 344 85 (24.7%) 104 (30.2%) 121 (35.2%) 34 (9.9%)
5 390 150 (38.5%) 157 (40.2%) 68 (17.4%) 15 (3.8%)
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virus-capture ELISA. In agreement with previous results obtained
from individuals with experimental primary DENV infection and sub-
jects with natural secondary infections, 38% (8/21) of the mAbs gen-
erated from individuals with a primary DENV infection exhibited
DENV reactivity, while 71% (25/35) of mAbs from secondary infection
plasmablasts exhibited DENV reactivity (Fig. 4a, Supplemental Table
3, Supplemental Fig. 7). The mAbs from secondary DENV infection
exhibited significant serotype cross-reactivity, while moderate bias
towards the infecting serotype was observed in mAbs from primary
infections (Fig. 4a). Notably, 47% (8/17) of the mAbs synthesized from
antibodies with a parental IgA isotype were DENV reactive. This is a
slightly lower rate than what was observed for IgG1 mAbs (76.6%, 23/
30), but indicates that a significant fraction of the IgA expressing plas-
mablasts found in circulation following acute DENV infection are
indeed virus-reactive.
Any mAb exhibiting DENV binding ability was subsequently
tested for DENV neutralization potential using a flow-cytometry
based microneutralization assay (Fig. 4b, Supplemental Table 3,
Fig. 3. Isotype distribution and somatic hypermutation burden of immunoglobulins expressed by circulating B cells during primary and secondary natural DENV infections. Immu-
noglobulin sequence analysis was restricted to cells from which a full-length heavy/light chain pair was successfully isolated and annotated by scRNAseq. (A) Isotype distribution of
immunoglobulins expressed by transcriptionally defined naïve B cells within all subjects at all time points captured in the dataset. (B) Isotype distribution of immunoglobulins
expressed by transcriptionally defined memory B cells within all subjects in all time points captured in the dataset. (C) Isotype distribution of immunoglobulins expressed by tran-
scriptionally defined plasmablast phenotype B cells within all subjects at all time points captured in the dataset. Plasmablasts and pre-plasmablasts were merged for this analysis.
(D) Total somatic hypermutation (SHM) burden of immunoglobulins expressed by naïve B cells from all subjects at all time points captured in this analysis. Analysis split by isotype.
(E) Total SHM burden of immunoglobulins expressed by memory B cells from all subjects at all time points captured in this analysis. Analysis split by isotype. (F) Total SHM burden
of immunoglobulins expressed by plasmablast phenotype B cells from all subjects at all time points captured in this analysis. Analysis split by isotype. Error bars +/- SEM. * p < 0.05,









% recovery Plasmablast isotype distribution (fully annotated)
IgM IgG IgA
Primary #1 1 38 35 92.11% 9 (26.5%) 4 (11.8%) 21 (61.8%)
3 79 73 92.41% 6 (8.3%) 22 (30.6%) 44 (61.1%)
Primary #2 1 236 222 94.07% 82 (36.9%) 55 (24.8%) 85 (38.3%)
5 40 36 90.00% 5 (13.9%) 24 (66.7%) 7 (19.4%)
Primary #3 1 26 21 80.77% 2 (10.5%) 4 (21.1%) 13 (68.4%)
2 154 133 86.36% 39 (29.8% 53 (40.4%) 39 (29.8%)
Secondary #1 0 435 396 91.03% 12 (3%) 352 (89.1%) 31 (7.8%)
1 549 494 89.98% 10 (2%) 428 (86.8%) 55 (11.2%)
7 9 8 88.89% 3 (37.5%) 5 (62.5%) 0 (0%)
Secondary #2 1 118 104 88.14% 3 (2.9%) 61 (59.2%) 39 (37.9%)
1 697 642 92.11% 17 (2.7%) 560 (87.4%) 64 (10%)
5 37 33 89.19% 6 (18.8%) 6 (18.8%) 20 (62.5%)
Secondary #3 0 61 54 88.52% 14 (25.9%) 22 (40.7%) 18 (33.3%)
1 155 141 90.97% 18 (12.8%) 82 (58.2%) 41 (29.1%)
5 83 75 90.36% 11 (14.7%) 40 (53.3%) 24 (32%)
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Fig. 4. DENV-elicited plasmablast-derived monoclonal antibody specificity and functional activity. (A) Heat map summary of the specificity and avidity of 61 mAbs derived from
immunoglobulin sequences extracted from the scRNAseq analysis of plasmablast-phenotype B cells from individuals experiencing primary or secondary natural DENV infections.
(B) Heat map summary of the neutralization potential (IC50) of 33 mAbs derived from immunoglobulin sequences extracted from the scRNAseq analysis of plasmablast-phenotype
B cells from individuals experiencing primary or secondary natural DENV infections. Only mAbs exhibiting DENV specificity by ELISA (EC50 < 5mg/ml) were assessed by FlowNT. (C)
Scatter plot of reciprocal DENV-1, 2, 3, and 4 IC50/EC50 values calculated for all plasmablast-derived mAbs generated in this study which exhibited an EC50 value of <5 mg/ml
for at least one viral serotype. Symbol color indicates the virus serotype tested (DENV-1 in blue, DENV-2 in red, DENV-3 in green, DENV-4 in purple). Symbol fill indicates if the anti-
body was isolated from an individual with a primary (open) or secondary (closed) DENV infection. (D) ADE potential of mAb VDB33 against DENV-1, 2, 3, and 4. All values are
shown as fold-increased infection compared to no antibody. Dashed line indicates the mAb IC50 as determined by FlowNT using the same viral preparation as used in the ADE assay.
(For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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Supplemental Fig. 7). mAbs from individuals experiencing primary
DENV infections exhibited relatively poor neutralization potential,
with only 37.5% (3/8) DENV reactive mAbs exhibiting any neutrali-
zation activity. In contrast, 92% (23/25) of the DENV-reactive mAbs
generated from individuals experiencing a secondary DENV infec-
tion exhibited viral neutralization, with 60% (15/25) capable of
neutralizing all 4 DENV serotypes to some degree. Of note, mAbs
generated from individuals experiencing secondary DENV infec-
tions often exhibited better binding and neutralization activity
towards serotypes other than the infecting virus at the time of
sample collection, potentially providing insight into the virologic
exposure history of the individual.
While the neutralization potential of a DENV-reactive mAb provides
some indication of its theoretical in vivo efficacy, the ratio between neu-
tralization potential and avidity is an important secondary consideration.
Antibodies requiring high viral occupancy in order to neutralize viral
infectivity  reflected in a high EC50/IC50 ratio  are potentially capable
of facilitating ADE in situations where they are present at a concentration
where they can bind a virus but not neutralize it if they possess an Fc
domain capable of interacting with Fc receptors expressed by DENV-sus-
ceptible leukocytes. Indeed, while some relationship is apparent between
the EC50 and IC50 values of the mAbs analyzed (Fig. 4c), many mAbs
sit above a theoretical linear line of identity for some DENV serotypes,
and therefore may be capable of facilitating ADE if they possessed an
appropriate Fc domain. Of particular note, mAb VDB33 demonstrated a
uniquely high EC50/IC50 ratio, as it potently binds all four DENV serotypes
(EC50 2.325.07 ng/ml) while showing poor neutralization potential (IC50
1181 to>10,000 ng/ml). Shotgunmutagenesis epitopemapping revealed
that this mAb bound the fusion loop of the DENV E protein, the canonical
binding site for antibodies thought to facilitate ADE (Fig. 6a). Indeed,
when tested in an in vitro ADE assay, VDB33 exhibited dramatic ADE
potential, especially against DENV3 (Fig. 4d). This is notable, as the indi-
vidual from which VDB33 was obtained was experiencing a secondary
DENV-3 infection (resulting in DHF) at the time of sample collection. A
contemporaneous serum sample from this individual exhibited a very
similar ADE profile as VDB33 (Supplemental Fig. 8). While it is not possi-
ble to draw a direct causal connection between this plasmablast-derived
antibody (or its relatives) and the clinical manifestation of DENV infection
observed in the individual from which it was isolated using these data,
these findings underscore the utility of assessing the molecular level
detail of DENV-elicited humoral immunity in future studies.
3.5. DENV-reactive serum immunoglobulin isotype diversity in primary
and secondary DENV infection
To determine if the DENV-elicited immunoglobulin isotype diver-
sity observed in the plasmablast compartment was reflected in the
contemporaneous antibodies in circulation, we performed DENV-
capture ELISA on serum samples from individuals with either pri-
mary or secondary DENV infection and quantified the relative pro-
portions of DENV-reactive IgM, IgG, and IgA present therein. To
provide temporal resolution to the analysis, four time-points per sub-
ject were analyzed: two samples during acute viral infection (acute 1,
acute 2), one sample obtained 37 days following fever abatement
(early-convalescent), and one sample collected 6 months post infec-
tion (Fig. 5, Supplemental Table 4).
Relatively modest DENV-reactive Ig levels were observed in acute
serum samples obtained from individuals with either primary
(Fig. 5a) or secondary (Fig. 5b) DENV-1 infections. However, a dra-
matic increase in circulating DENV-reactive Igs was observed in
early-convalescent serum samples from both primary and secondary
DENV infections (Fig. 5a and b). Notably, while DENV-reactive IgA
was detectable in all subjects at this time point, IgA represented a
much higher fraction of the total DENV-reactive Ig pool in individuals
experiencing a primary DENV infection, while IgG production domi-
nated in secondary DENV-1 infections (Fig. 5a and b). Total DENV-
reactive Ig titers returned to more modest levels in all subjects by 6
months post infection, with little DENV-reactive IgA observed (Fig. 5a
and b). Therefore, despite the fact that DENV-reactive IgA represent
an appreciable fraction of the total DENV-reactive Ig in circulation
just following the resolution of infection  especially in individuals
experiencing a primary DENV infection - DENV-reactive IgA does not
appear to persist in circulation.
To further validate these observations, single-dilution ELISA anal-
ysis was performed on acute and convalescent serum samples from
an additional 9 individuals experiencing either a primary or second-
ary DENV-1 infection (Supplemental Table 5). As was observed in the
limiting-dilution ELISA analysis, relatively little DENV-reactive IgG or
IgA was observed in acute infection time points from subjects with
either primary or secondary infection (Fig. 5c). However, the DENV-
reactive IgG and IgA signals increased dramatically in the corre-
sponding early convalescent serum samples, with IgA comprising a
much higher fraction of the total DENV-reactive Ig signal in samples
from primary DENV-1 infections than from samples from secondary
infections (Fig. 5d). These data confirm that DENV-reactive IgA repre-
sents a significant fraction of the total DENV-reactive Ig pool follow-
ing the resolution of acute infection, especially in individuals
experiencing a primary DENV infection.
3.6. Epitope specificity of plasmablast-derived/DENV-reactive mAbs
In light of the unexpectedly high frequency of DENV-reactive IgA
clones observed in our dataset and the pervasiveness of DENV-reactive
IgA in contemporaneous serum samples especially in individuals
experiencing a primary DENV infection - we endeavored to determine
if DENV-reactive IgA Igs recognize an unconventional epitope on
DENV or if their antigen specificity mirrored that of other “conven-
tional” DENV-reactive antibody isotypes. To this end, we utilized shot-
gun mutagenesis epitope mapping of prM/E from DENV-1 (strain
Nauru/West Pac/1974) and DENV-2 (strain 16681) to determine the
binding specificity of six parentally IgG1 and IgA1 mAbs identified in
subjects with either primary or secondary DENV infections.
The three parentally IgG1 DENV-reactive mAbs picked for epitope
mapping were found to exclusively interact with the fusion loop region
of the DENV E protein (Fig. 6a, Supplemental Table 6). Three parentally
IgA mAbs generated from subjects with primary or secondary DENV
infections were observed to either bind the DENV E protein fusion loop
(VDB31/VDB50) or the DENV E protein domain II hinge region (VDB37)
(Fig. 6b, Supplemental Table 6). These results indicate that DENV-
reactive IgA antibodies are capable of recognizing multiple distinct
epitopes on the DENV E protein even in individuals who have not pre-
viously encountered DENV, and that DENV-reactive IgG and IgA isotype
antibodies can overlap in their epitope specificity.
4. Discussion
In this study, we utilized single cell RNA sequencing technology to
assess the clonal and transcriptional diversity of plasmablasts elicited
in response to primary and secondary DENV infections in an unbiased
and high-throughput fashion. We found that an unexpectedly high
proportion of DENV-elicited plasmablasts expressed IgA Igs, notably
in individuals experiencing a primary DENV infection. These IgA
immunoglobulins were extensively hypermutated, even in individu-
als with serologically confirmed primary DENV infection. Utilizing a
combination of conventional biochemical assays and high-through-
put shotgun mutagenesis, we determined that DENV-reactive IgA
antibodies represented a significant fraction of DENV-reactive Igs
generated in response to DENV infection, and that they have a over-
lapping epitope specificity to “conventional” DENV-reactive IgM and
IgG class-switched antibodies reported in the literature [36,38,59,60].
These results provide insight into the molecular-level diversity of
DENV-elicited humoral immunity, and suggest a hitherto
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Fig. 5. Kinetics and magnitude of DENV-reactive IgM/IgG/IgA in circulation following primary or secondary DENV infection. (A) Limiting dilution DENV-1 capture ELISA analysis of
relative virus-reactive IgG, IgA, IgM levels present in serum obtained from three subjects with serologically- and PCR-confirmed primary DENV-1 infections. (B) Limiting dilution
DENV-1 capture ELISA analysis of relative virus-reactive IgG, IgA, IgM levels present in serum obtained from three subjects with serologically- and PCR-confirmed secondary DENV-
1 infections. (C) Single-dilution DENV-1 capture ELISA analysis of the relative virus-reactive IgG, IgA, IgM levels present in acute infection serum samples obtained from subjects
with serologically and PCR confirmed primary (n = 5) and secondary (n = 4) DENV-1 infections. (D) Single-dilution DENV-1 capture ELISA analysis of the relative virus-reactive IgG,
IgA, IgM levels present in early-convalescent serum samples obtained from subjects with serologically and PCR confirmed primary and secondary DENV-1 infections. Error bars indi-
cate +/- SEM. ** p < 0.01, one-way ANOVA.
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unappreciated role for DENV-reactive IgA in the humoral response to
DENV infection, especially in the setting of primary DENV infection.
In addition to revealing a potential role for DENV-reactive IgA in
the setting of acute DENV infection, the data presented in this study
provide molecular-level resolution and reinforcement to several fun-
damental features of DENV-elicited humoral immunity. This includes
the observations that the majority of the individual antibody clones
elicited by a primary DENV infection exhibit relatively poor neutrali-
zation activity, and the serotype cross-reactive humoral immune pro-
file associated with secondary DENV infections extends to the level of
individual antibody clones. Our findings must be considered in light
of several limitations, however. These data were generated by the
analysis of samples obtained from a small number of children, most
of whom were experiencing DENV-1 infections. Although viral tro-
pism and clinical manifestations of the different DENV serotypes are
thought to be similar, some caution must be used in extrapolating
these observations to other age groups and to other DENV serotypes.
Immunological history and host/pathogen genetics both play signifi-
cant roles in determining the pathogenesis and cellular/molecular
level response to DENV infection [61]. However, tools such as scRNA-
seq and other high-throughput/high-resolution modalities can now
reliably capture many of these complex variables, hopefully provid-
ing better insight and more actionable information in the setting of
acute DENV infection.
The induction of virus specific IgA in response to acute infection is not
an uncommon phenomenon, especially for viruses that exhibit significant
mucosal tropism [62]. The unique cytokine environment found in muco-
sal tissues is thought to provide the necessary immunological cues to nas-
cently activated B cells to facilitate the IgA1 antibody class-switch event
[63]. However, DENV has no known mucosal involvement either during
transmission or replication. DENV-reactive IgA generated in response to
acute infection is not without precedent, although much of the previous
work on IgA in the context of DENV infection has focused on the feasibil-
ity of utilizing urine/saliva restricted DENV-reactive IgA as a non-invasive
diagnostic [6467]. A single paper has compared directly the titers of IgA
in primary and secondary DENV infections [67], and no previous study
has assessed the prevalence of IgA class-switched plasmablasts present
following acute DENV infection. The paucity of previous data on the
abundance and specificity of DENV-specific IgA following acute viral
infection is partially attributable to the relatively brief window during
which significant levels of these DENV-reactive IgA antibodies are present
in serum following primary DENV infection (only in early convalescent
serum samples in our study). In addition, the majority of previous studies
assessing the molecular diversity of DENV-elicited humoral immunity
also intentionally limited their analysis to include IgG and IgM antibodies
proteins and/or genes [32,3537].
Although the precise role  if any - that DENV-elicited IgA plays in
influencing the immunopathogenesis of DENV is still unclear, it is
noteworthy that while we have demonstrated that the antigen-bind-
ing domains of DENV-elicted IgA clones can effectively neutralize
DENV infectivity, the restricted expression profile of IgA Fc receptors
implies that DENV-reactive IgA clones cannot easily facilitate classical
antibody-dependent immune enhancement of DENV infection.
Therefore, much like IgM, DENV-reactive IgA might contribute neu-
tralizing activity to DENV-reactive serum, while antagonizing IgG1
mediated ADE. As the average neutralization potential of the DENV-
reactive IgA clones tested in this study varied widely, the ability of
these clones to neutralize DENV in a complex humoral environment
may be limited, even if these antibodies were present at an equimolar
ratio as their IgG counterparts during the resolution phase of a DENV
infection. However, the epitope mapping data presented herein sug-
gests that at least some DENV-reactive IgA clones are capable of bind-
ing the same epitopes as their IgG1 counterparts. Therefore, it is
possible that DENV-specific IgA may limit intra-host viral propaga-
tion during the resolution phase of an acute DENV infection by com-
peting with infection-enhancing DENV-specific IgG and preventing
internalization of infectious virions through IgG Fc receptors. This
scenario does not necessitate that an IgA opsonized virus is less infec-
tious than a un-opsonized virus in the context of Fc-receptor inde-
pendent infection, but it does suggest that an IgA opsonized virus
might be less infectious than an IgG1 opsonized virus from the stand-
point of a cell expressing an IgG1-reactive Fc receptor.
In light of the consistently high SHM burden observed in IgA
expressing plasmablasts circulating in response to primary DENV
infection, we additionally propose that the majority of these cells are
reactivated memory B cells that were initially stimulated by an anti-
gen other than DENV. Memory B cells have both a numerical and
functional advantage over naïve B cells upon antigen engagement,
and a relatively small population of memory B cells that happen to
cross-react with DENV in addition to their “cognate” antigen could
certainly be expected to contribute to a primary response to infec-
tion. Furthermore, it is perhaps unsurprising that a small number of
IgA class-switched memory B cells with some degree of DENV cross
reactivity exist in any individual prior to a primary DENV infection, as
it has been suggested that more than 70% of the total antibody pro-
duction in humans is IgA in isotype, albeit mostly at mucosal surfaces
[68]. Therefore, it is possible that all primary pathogen infections
include a significant IgA component, as the largest pool of pre-exist-
ing memory B cells that is subsequently capable of responding/cross-
reacting with a “novel” antigen would be IgA in isotype. This inter-
pretation follows the concept of “original antigen sin”, wherein a pre-
vious infection has a direct impact on the specificity and efficacy of
immunity generated in response to a subsequent infection/challenge,
but extends the concept to primary DENV infection [69]. This indeli-
ble feature of pre-existing immunity can also be observed in our data
from secondary DENV infections, wherein antibody specificity is
occasionally biased towards DENV serotypes other than the infecting
type. These data suggest that immunological memory generated in
response to completely different stimuli may impact future immune
responses simply because of putative antigenic similarity.
Declaration of Competing Interest
A.T.W reports grants from Military Infectious Disease Research
Program, during the conduct of the study.
Fig. 6. Binding specificity of plasmablast-derived/DENV-reactive monoclonal antibod-
ies. (A) Shotgun mutagenesis epitope mapping data from IgG1-derived mAbs. (B) Shot-
gun mutagenesis epitope mapping data from IgA1-derived mAbs. Color scheme for
indicated residues: green = fusion loop, yellow = domain II hinge region. (For interpre-
tation of the references to color in this figure legend, the reader is referred to the web
version of this article.)
12 A.T. Waickman et al. / EBioMedicine 54 (2020) 102733
B.J.D, E.D., M.E.F, A.G., J.L., and A.L.R. reports grants from National Insti-
tute of Allergy and Infectious Diseases, during the conduct of the study.
B.J.D. reports other support from Integral Molecular, outside the
submitted work.
S.J.T reports other support fromUS DoD, other support fromGSK, dur-
ing the conduct of the study; personal fees and other support from GSK
Vaccines, personal fees and other support from Takeda, personal fees and
other support from Merck, personal fees and other support from Prime-
Vax, personal fees and other support from Themisbio, personal fees and
other support from Chugai Pharma, personal fees and other support from
Cormac Life Sciences, personal fees and other support from HHS NVPO /
Tunnel Govt Services, personal fees and other support from Janssen,
other support from GreenMark Partners, personal fees from Tremeau
Pharma, outside the submitted work; In addition, Dr. Thomas has a pat-
ent US10086061B2 (combined flavivirus vaccines) issued.




This work was supported by the Military Infectious Disease
Research Program (MIDRP), the Congressionally Directed Medical
Research Program (CDMRP), and the National Institutes of Allergy and
Infectious Disease (NIAID, P01AI034533, Rothman). The epitope map-
ping analysis was supported by the NIH contract HHSN272201400058C
(BJD). These funders had any no role in study design, data collection,
data analysis, interpretation, or writing of this report.
Data availability
The authors declare that all data supporting the findings of this
study are available within this article and its Supplementary Informa-
tion files, or from the corresponding author upon reasonable request.
Single-cell RNAseq gene expression data have been deposited in the
Gene Expression Omnibus database (GSE145307).
Disclaimer
The opinions or assertions contained herein are the private views
of the authors and are not to be construed as reflecting the official
views of the US Army or the US Department of Defense, or the
National Institutes of Health. Material has been reviewed by the Wal-
ter Reed Army Institute of Research. There is no objection to its pre-
sentation and/or publication. The investigators have adhered to the
policies for protection of human subjects as prescribed in AR 7025.
Supplementary materials
Supplementary material associated with this article can be found
in the online version at doi:10.1016/j.ebiom.2020.102733.
References
[1] Gubler DJ. Aedes aegypti and aedes aegypti-borne disease control in the 1990s:
top down or bottom up. Charles Franklin Craig lecture. Am J Trop Med Hyg.
1989;40(6):571–8.
[2] Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global
distribution and burden of dengue. Nature 2013;496(7446):504–7.
[3] Shepard DS, Coudeville L, Halasa YA, Zambrano B, Dayan GH. Economic impact of
dengue illness in the Americas. Am J Trop Med Hyg 2011;84(2):200–7.
[4] Guzman MG, Harris E. Dengue. Lancet 2015;385(9966):453–65.
[5] Sangkawibha N, Rojanasuphot S, Ahandrik S, Viriyapongse S, Jatanasen S, Salitul V,
et al. Risk factors in dengue shock syndrome: a prospective epidemiologic study in
Rayong, Thailand. I. The 1980 outbreak. Am J Epidemiol 1984;120(5):653–69.
[6] Thein S, Aung MM, Shwe TN, Aye M, Zaw A, Aye K, et al. Risk factors in dengue
shock syndrome. Am J Trop Med Hyg 1997;56(5):566–72.
[7] Yoon IK, Srikiatkhachorn A, Hermann L, Buddhari D, Scott TW, Jarman RG, et al.
Characteristics of mild dengue virus infection in Thai children. Am J Trop Med
Hyg 2013;89(6):1081–7.
[8] Burke DS, Nisalak A, Johnson DE, Scott RM. A prospective study of dengue infec-
tions in Bangkok. Am J Trop Med Hyg 1988;38(1):172–80.
[9] Rothman AL. Immunity to dengue virus: a tale of original antigenic sin and tropi-
cal cytokine storms. Nat Rev Immunol 2011;11(8):532–43.
[10] Lan NT, Hirayama K. Host genetic susceptibility to severe dengue infection. Trop
Med Health 2011;39(4 Suppl):73–81.
[11] Katzelnick LC, Gresh L, Halloran ME, Mercado JC, Kuan G, Gordon A, et al. Anti-
body-dependent enhancement of severe dengue disease in humans. Science
2017;358(6365):929–32.
[12] Halstead SB. Immune enhancement of viral infection. Prog Allergy 1982;31:301–64.
[13] Halstead SB. Dengue: hematologic aspects. Semin Hematol 1982;19(2):116–31.
[14] Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS. Antibody-dependent enhance-
ment of dengue virus growth in human monocytes as a risk factor for dengue
hemorrhagic fever. Am J Trop Med Hyg 1989;40(4):444–51.
[15] Zellweger RM, Prestwood TR, Shresta S. Enhanced infection of liver sinusoidal
endothelial cells in a mouse model of antibody-induced severe dengue disease.
Cell Host Microbe 2010;7(2):128–39.
[16] Wang TT, Sewatanon J, Memoli MJ, Wrammert J, Bournazos S, Bhaumik SK, et al.
IgG antibodies to dengue enhanced for FcgammaRIIIA binding determine disease
severity. Science 2017;355(6323):395–8.
[17] Kou Z, Lim JY, Beltramello M, Quinn M, Chen H, Liu S, et al. Human antibodies
against dengue enhance dengue viral infectivity without suppressing type i inter-
feron secretion in primary human monocytes. Virology 2011;410(1):240–7.
[18] Blackley S, Kou Z, Chen H, Quinn M, Rose RC, Schlesinger JJ, et al. Primary human
splenic macrophages, but not t or b cells, are the principal target cells for dengue
virus infection in vitro. J Virol 2007;81(24):13325–34.
[19] Rodenhuis-Zybert IA, Moesker B, da Silva Voorham JM, van der Ende-Metselaar H,
Diamond MS, Wilschut J, et al. A fusion-loop antibody enhances the infectious
properties of immature flavivirus particles. J Virol 2011;85(22):11800–8.
[20] Halstead SB. Dengue antibody-dependent enhancement: knowns and unknowns.
Microbiol Spectr 2014;2(6):1–18.
[21] Halstead SB, Venkateshan CN, Gentry MK, Larsen LK. Heterogeneity of infection
enhancement of dengue 2 strains by monoclonal antibodies. J Immunol 1984;132
(3):1529–32.
[22] Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpi-
tikul W, et al. Cross-reacting antibodies enhance dengue virus infection in
humans. Science 2010;328(5979):745–8.
[23] Shlomchik MJ, Weisel F. Germinal center selection and the development of mem-
ory b and plasma cells. Immunol Rev 2012;247(1):52–63.
[24] Nutt SL, Hodgkin PD, Tarlinton DM, Corcoran LM. The generation of antibody-
secreting plasma cells. Nat Rev Immunol 2015;15(3):160–71.
[25] Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KG, Dorner T, et al.
Competence and competition: the challenge of becoming a long-lived plasma
cell. Nat Rev Immunol 2006;6(10):741–50.
[26] Yoshida T, Mei H, Dorner T, Hiepe F, Radbruch A, Fillatreau S, et al. Memory b and
memory plasma cells. Immunol Rev 2010;237(1):117–39.
[27] Benner R, Hijmans W, Haaijman JJ. The bone marrow: the major source of serum
immunoglobulins, but still a neglected site of antibody formation. Clin Exp Immu-
nol 1981;46(1):1–8.
[28] Slifka MK, Matloubian M, Ahmed R. Bone marrow is a major site of long-term
antibody production after acute viral infection. J Virol 1995;69(3):1895–902.
[29] Chu VT, Berek C. The establishment of the plasma cell survival niche in the bone
marrow. Immunol Rev 2013;251(1):177–88.
[30] Nakaya HI, Wrammert J, Lee EK, Racioppi L, Marie-Kunze S, Haining WN, et al.
Systems biology of vaccination for seasonal influenza in humans. Nat Immunol
2011;12(8):786–95.
[31] Jackson KJ, Liu Y, Roskin KM, Glanville J, Hoh RA, Seo K, et al. Human responses to
influenza vaccination show seroconversion signatures and convergent antibody
rearrangements. Cell Host Microbe 2014;16(1):105–14.
[32] Wrammert J, Onlamoon N, Akondy RS, Perng GC, Polsrila K, Chandele A, et al.
Rapid and massive virus-specific plasmablast responses during acute dengue
virus infection in humans. J Virol 2012;86(6):2911–8.
33 ] Balakrishnan T, Bela-Ong DB, Toh YX, Flamand M, Devi S, Koh MB, et al. Dengue
virus activates polyreactive, natural IgG B cells after primary and secondary infec-
tion. PLoS ONE 2011;6(12):e29430.
[34] Haltaufderhyde K, Srikiatkhachorn A, Green S, Macareo L, Park S, Kalayanarooj S,
et al. Activation of peripheral T follicular helper cells during acute dengue virus
infection. J Infect Dis 2018;218(10):1675–85.
[35] Appanna R, Kg S, Xu MH, Toh YX, Velumani S, Carbajo D, et al. Plasmablasts during
acute dengue infection represent a small subset of a broader virus-specific mem-
ory B cell pool. EBioMedicine 2016;12:178–88.
[36] Xu M, Hadinoto V, Appanna R, Joensson K, Toh YX, Balakrishnan T, et al. Plasma-
blasts generated during repeated dengue infection are virus glycoprotein-specific
and bind to multiple virus serotypes. J Immunol 2012;189(12):5877–85.
[37] Priyamvada L, Cho A, Onlamoon N, Zheng NY, Huang M, Kovalenkov Y, et al. B cell
responses during secondary dengue virus infection are dominated by highly
cross-reactive, memory-derived plasmablasts. J Virol. 2016;90(12):5574–85.
[38] Nivarthi UK, Tu HA, Delacruz MJ, Swanstrom J, Patel B, Durbin AP, et al. Longitudi-
nal analysis of acute and convalescent b cell responses in a human primary den-
gue serotype 2 infection model. EBioMedicine 2019;41:465–78.
A.T. Waickman et al. / EBioMedicine 54 (2020) 102733 13
[39] de Alwis R, Beltramello M, Messer WB, Sukupolvi-Petty S, Wahala WM, Kraus A,
et al. In-depth analysis of the antibody response of individuals exposed to pri-
mary dengue virus infection. PLoS Negl Trop Dis 2011;5(6):e1188.
[40] Sabin AB. Research on dengue during World War II. Am J Trop Med Hyg 1952;1
(1):30–50.
[41] Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S,
et al. Dengue in the early febrile phase: viremia and antibody responses. J Infect
Dis 1997;176(2):322–30.
[42] Kalayanarooj S, Vaughn DW, Nimmannitya S, Green S, Suntayakorn S, Kunentra-
sai N, et al. Early clinical and laboratory indicators of acute dengue illness. J Infect
Dis 1997;176(2):313–21.
[43] Libraty DH, Endy TP, Houng HS, Green S, Kalayanarooj S, Suntayakorn S, et al. Dif-
fering influences of virus burden and immune activation on disease severity in
secondary dengue-3 virus infections. J Infect Dis 2002;185(9):1213–21.
[44] Innis BL, Nisalak A, Nimmannitya S, Kusalerdchariya S, Chongswasdi V, Suntaya-
korn S, et al. An enzyme-linked immunosorbent assay to characterize dengue
infections where dengue and Japanese encephalitis co-circulate. Am J Trop Med
Hyg 1989;40(4):418–27.
[45] Zheng GX, Terry JM, Belgrader P, Ryvkin P, Bent ZW, Wilson R, et al. Massively par-
allel digital transcriptional profiling of single cells. Nat Commun 2017;8:14049.
[46] Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck 3rd WM, et al.
Comprehensive integration of single-cell data. Cell 2019;177(7):1888–902 e21.
[47] Butler A, Hoffman P, Smibert P, Papalexi E, Satija R. Integrating single-cell tran-
scriptomic data across different conditions, technologies, and species. Nat Bio-
technol 2018;36(5):411–20.
[48] Lee DW, Khavrutskii IV, Wallqvist A, Bavari S, Cooper CL, Chaudhury S. BRILIA:
integrated tool for high-throughput annotation and lineage tree assembly of B-
cell repertoires. Front Immunol 2016;7:681.
[49] Aouinti S, Giudicelli V, Duroux P, Malouche D, Kossida S, Lefranc MP. IMGT/StatClono-
type for pairwise evaluation and visualization of NGS IG and TR IMGT clonotype (AA)
diversity or expression from IMGT/HighV-quest. Front Immunol 2016;7:339.
[50] Kraus AA, Messer W, Haymore LB, de Silva AM. Comparison of plaque- and flow
cytometry-based methods for measuring dengue virus neutralization. J Clin
Microbiol 2007;45(11):3777–80.
[51] de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, et al. Iden-
tification of human neutralizing antibodies that bind to complex epitopes on den-
gue virions. Proc Natl Acad Sci U S A 2012;109(19):7439–44.
[52] McCracken MK, Gromowski GD, Friberg HL, Lin X, Abbink P, De La Barrera R, et al.
Impact of prior flavivirus immunity on Zika virus infection in rhesus macaques.
PLoS Pathog 2017;13(8):e1006487.
[53] Davidson E, Doranz BJ. A high-throughput shotgun mutagenesis approach to
mapping B-cell antibody epitopes. Immunology 2014;143(1):13–20.
[54] Rodenhuis-Zybert IA, Wilschut J, Smit JM. Dengue virus life cycle: viral and host
factors modulating infectivity. Cell Mol Life Sci 2010;67(16):2773–86.
[55] Kurane I, Innis BL, Nimmannitya S, Nisalak A, Meager A, Janus J, et al. Activation of
t lymphocytes in dengue virus infections. High levels of soluble interleukin 2
receptor, soluble CD4, soluble CD8, interleukin 2, and interferon-gamma in sera
of children with dengue. J Clin Invest 1991;88(5):1473–80.
[56] Boonpucknavig S, Lohachitranond C, Nimmanitya S. The pattern and nature of the
lymphocyte population response in dengue hemorrhagic fever. Am J Trop Med
Hyg 1979;28(5):885–9.
[57] Friberg H, Bashyam H, Toyosaki-Maeda T, Potts JA, Greenough T, Kalayanarooj S,
et al. Cross-reactivity and expansion of dengue-specific t cells during acute pri-
mary and secondary infections in humans. Sci Rep 2011;1:51.
[58] Jourdan M, Caraux A, Caron G, Robert N, Fiol G, Reme T, et al. Characterization of a
transitional preplasmablast population in the process of human b cell to plasma
cell differentiation. J Immunol 2011;187(8):3931–41.
[59] Dejnirattisai W, Wongwiwat W, Supasa S, Zhang X, Dai X, Rouvinski A, et al. A
new class of highly potent, broadly neutralizing antibodies isolated from viremic
patients infected with dengue virus. Nat Immunol 2015;16(2):170–7.
[60] Lok SM, Ng ML, Aaskov J. Amino acid and phenotypic changes in dengue 2 virus
associated with escape from neutralisation by IgM antibody. J Med Virol 2001;65
(2):315–23.
[61] Martina BE, Koraka P, Osterhaus AD. Dengue virus pathogenesis: an integrated
view. Clin Microbiol Rev 2009;22(4):564–81.
[62] Corthesy B. Multi-faceted functions of secretory IgA at mucosal surfaces. Front
Immunol 2013;4:185.
[63] Cerutti A. The regulation of IgA class switching. Nat Rev Immunol 2008;8(6):421–34.
[64] Nawa M, Takasaki T, Ito M, Inoue S, Morita K, Kurane I. Immunoglobulin A anti-
body responses in dengue patients: a useful marker for serodiagnosis of dengue
virus infection. Clin Diagn Lab Immunol 2005;12(10):1235–7.
[65] Balmaseda A, Guzman MG, Hammond S, Robleto G, Flores C, Tellez Y, et al. Diag-
nosis of dengue virus infection by detection of specific immunoglobulin M (IgM)
and IgA antibodies in serum and saliva. Clin Diagn Lab Immunol 2003;10(2):
317–22.
[66] Zhao H, Qiu S, Hong WX, Song KY, Wang J, Yang HQ, et al. Dengue specific immu-
noglobulin a antibody is present in urine and associated with disease severity. Sci
Rep 2016;6:27298.
[67] Vazquez S, Cabezas S, Perez AB, Pupo M, Ruiz D, Calzada N, et al. Kinetics of anti-
bodies in sera, saliva, and urine samples from adult patients with primary or sec-
ondary dengue 3 virus infections. Int J Infect Dis 2007;11(3):256–62.
[68] Kerr MA. The structure and function of human IgA. Biochem J 1990;271(2):285–96.
[69] Halstead SB, Rojanasuphot S, Sangkawibha N. Original antigenic sin in dengue.
Am J Trop Med Hyg 1983;32(1):154–6.
14 A.T. Waickman et al. / EBioMedicine 54 (2020) 102733
